Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9735825 | 0.87 | MMP12 (0.35) | ADRB2ADRB1ADRB3 | |
| SCHEMBL3911872 | 0.84 | PTPRC (0.35) | PTPRCAAK1ADRB2ADRB1ADRB3 | |
| SCHEMBL29666570 | 0.82 | AAK1 (0.35) | PTPRCAAK1ABCB1CA2CA9 | |
| SCHEMBL13345438 | 0.82 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ABCB1 | |
| SCHEMBL7870035 | 0.82 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ABCB1 | |
| SCHEMBL7870032 | 0.82 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ABCB1 | |
| SCHEMBL29064066 | 0.80 | MMP12 (0.37) | ADRB2ADRB1ADRB3KDM4EALDH1A1 | |
| SCHEMBL9735944 | 0.80 | MMP12 (0.37) | ADRB2ADRB1ADRB3KDM4EALDH1A1 | |
| SCHEMBL28950487 | 0.80 | TRPA1 (0.38) | AAK1ABCB1 | |
| SCHEMBL28950485 | 0.80 | TRPA1 (0.38) | AAK1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631533-B1 | NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF BETA-KETOESTERS | BIOCON LTD (IN) | 2009-03-11 | — | — | EP | disclosed |
| US-7232920-B2 | Process for stereoselective reduction of β-ketoesters | BIOCON (IN) | 2007-06-19 | — | — | US | disclosed |
| EP-1631533-A4 | NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF BETA-KETOESTERS | BIOCON LTD (IN) | 2007-04-25 | — | — | EP | disclosed |
| EP-1631533-A1 | NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF BETA-KETOESTERS | Biocon Limited (IN) | 2006-03-08 | — | — | EP | disclosed |
| US-20040259946-A1 | Novel process for stereoselective reduction of b ketoesters | BIOCON LIMITED (IN) | 2004-12-23 | — | — | US | disclosed |
| WO-2004094343-A1 | NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF ß-KETOESTERS | BIOCON LIMITED (IN) | 2004-11-04 | — | — | WO | disclosed |
| US-4977279-A | Anticholesterol agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-12-11 | — | — | US | disclosed |
| US-4970313-A | Optically active 3-demethylmevalonic acid derivatives, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259946-A1 | Novel process for stereoselective reduction of b ketoesters | CBR3, CBR1, AKR1B1 | PTPRC 1633/4885AAK1 2844/4885ADRB2 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.